Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
P/S (TTM)
0.2
VBI Vaccines Inc. is a biopharmaceutical firm dedicated to the development and commercialization of vaccines, targeting both infectious diseases and immuno-oncology. Among its commercial offerings is Sci-B-Vac, a prophylactic vaccine designed to prevent hepatitis B (HBV). The company is also actively developing VBI-2601 (also identified as BRII-179), an investigational immunotherapeutic aimed at treating chronic hepatitis B infection. A cornerstone of its research and development is the proprietary enveloped virus-like particle (eVLP) platform. This technology facilitates the creation of eVLP vaccines engineered to mimic viral structures, thereby effectively prompting a human immune response. Among the primary candidates leveraging this eVLP platform are VBI-1901, an immunotherapeutic vaccine targeting glioblastoma, which is currently undergoing Phase I/IIa clinical study, and VBI-1501, a prophylactic vaccine candidate against cytomegalovirus, having already completed its Phase I clinical trial. Further enhancing its pipeline, VBI is developing several coronavirus vaccine candidates, including VBI-2902 and VBI-2901. Beyond its direct pipeline, the company also engages in the strategic development of vaccine platforms and products designed for out-licensing to other pharmaceutical and biotechnology entities. VBI maintains significant collaborative and licensing agreements with key partners such as Brii Biosciences Limited and GlaxoSmithKline Biologicals S.A. Furthermore, it collaborates with the National Research Council of Canada to develop a broad-spectrum pan-coronavirus vaccine targeting COVID-19, SARS, and MERS. A partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) aims to advance vaccine candidates specifically against emerging COVID-19 variants. Originally established as SciVac Therapeutics Inc., the company rebranded to VBI Vaccines Inc. in May 2016. Its corporate headquarters are situated in Cambridge, Massachusetts.
www.vbivaccines.comNo one on the platform currently holds VBIV.
No tracked institution reports a position in VBIV as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-04-12 | 1-for-30reverse |
No one on the platform has traded VBIV yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 702.4% | 20.9% | ||||
| Profit Margin % | -1069.3% | -6515.8% | ||||
| Free Cash Flow Margin % | -711.2% | -4290.4% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $59M | +73.1% | $-0.23 | $-0.23–$-0.23 | — | 1 |
| 2027 | $97M | +64.1% | $0.07 | $0.07–$0.07 | 0.9× | 1 |
| 2028 | $154M | +59.4% | $0.40 | $0.40–$0.40 | 0.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2024-05-15 | $-0.53 | $-0.55 | -3.8% |
| 2024-04-16 | $-0.22 | $-0.01 | +95.5% |
| 2023-11-14 | $-0.14 | $-0.38 | -171.4% |
| 2023-08-14 | $-2.16 | $-2.17 | -0.5% |
| 2023-05-15 | $-2.27 | $-2.43 | -7.0% |
| 2023-03-13 | $-2.10 | $-2.40 | -14.3% |
| 2022-11-10 | $-2.40 | $-0.09 | +96.3% |
| 2022-08-08 | $-2.10 | $-2.70 | -28.6% |
| $2M |
| — |
| MTPMidatech Pharma plc | $0.29 | -18.50% | $2M | — |
| NBSENeuBase Therapeutics, Inc. | $0.38 | -1.56% | $1M | — |
Source: Financial Modeling Prep · peers by sector/industry
@thelibsrdum exactly…so many of them sound alike…im holding 30k shares of $IBRX and it scares me that the cult-like posts resemble $VBIV which I lost a few hundred thousand dollars on…everyone’s jacked about institutional ownership (doesnt mean shit) and all kinds of hiring going on (doesnt mean shit) and we’re going to save the world (cancer for IBRX, covid for VBIV)
View on StockTwits ↗
Next-gen vaccine delivery about to have its moment: $BIOV leading with no-oil DPX (RSV Phase1 93% response, mRNA carrier incoming) $VBIV VBI-2900 series $DVAX CpG dominance $GRTS het-rec platform One big readout and the whole group rerates. Eyes on McMaster update 👀
View on StockTwits ↗
$VBIV Unfortunately, I lost a lot in this fraud and wanted to know if there were any asset classes action where I could still try to recover something Thanks
View on StockTwits ↗
@MarkolinoDimond @Slynchy29 i burned my fingers with 21k going up in smoke with $VBIV great story, really excited to support vaccine against brain tumors and the mofos took my money and bye
View on StockTwits ↗@Pentium @Fire7878 dollar cost averaging…great strategy….for mutual funds…anyone doing this approach in the bio sector will lose in the long term…i heard the same chest thumpers on $VBIV as they averaged down all the way to zero…the chances of picking 4-5 winners in a row in this sector and using this strategy is extremely low
View on StockTwits ↗@Creisi reasonably sure youre wrong…but hope youre right…in sitting on 50k shares that ive pretty much chalked off as total loss based on my extensive experience in similar situations…most recently $VBIV
View on StockTwits ↗
@gc358 same thing holders of $VBIV kept saying….and in the end the shorts won…just saying I think the impact of shorts is overrated
View on StockTwits ↗
$VBIV wow, haven't been here in 5 years.... sucks... made $$$ in 2020.
View on StockTwits ↗
$VBIV just wanted to see if there are any of the OG retards still hanging around here. In a way, glad you lost all your money for being absolute fuckheads. Also hope you never recover and maybe burn in Hell for all the BS influencing youve done over a better part of 4-5 years. You truly are the scum of the earth. Wish you nothing but the worst because you are excrement.
View on StockTwits ↗$VBIV I see there are still a few OGs here, who have hopefully moved on to greener pastures by now. @WiseInvestor1 and I now swing trade $WB regularly and patiently waiting their dividend payout in early April.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.